Back to Search Start Over

Silencing of BCR/ABL Chimeric Gene in Human Chronic Myelogenous Leukemia Cell Line K562 by siRNA-Nuclear Export Signal Peptide Conjugates.

Authors :
Shinkai Y
Kashihara S
Minematsu G
Fujii H
Naemura M
Kotake Y
Morita Y
Ohnuki K
Fokina AA
Stetsenko DA
Filichev VV
Fujii M
Source :
Nucleic acid therapeutics [Nucleic Acid Ther] 2017 Jun; Vol. 27 (3), pp. 168-175. Date of Electronic Publication: 2017 Mar 29.
Publication Year :
2017

Abstract

Herein we described the synthesis of siRNA-NES (nuclear export signal) peptide conjugates by solid phase fragment coupling and the application of them to silencing of bcr/abl chimeric gene in human chronic myelogenous leukemia cell line K562. Two types of siRNA-NES conjugates were prepared, and both sense strands at 5' ends were covalently linked to a NES peptide derived from TFIIIA and HIV-1 REV, respectively. Significant enhancement of silencing efficiency was observed for both of them. siRNA-TFIIIA NES conjugate suppressed the expression of BCR/ABL gene to 8.3% at 200 nM and 11.6% at 50 nM, and siRNA-HIV-1REV NES conjugate suppressed to 4.0% at 200 nM and 6.3% at 50 nM, whereas native siRNA suppressed to 36.3% at 200 nM and 30.2% at 50 nM. We could also show complex of siRNA-NES conjugate and designed amphiphilic peptide peptideβ7 could be taken up into cells with no cytotoxicity and showed excellent silencing efficiency. We believe that the complex siRNA-NES conjugate and peptideβ7 is a promising candidate for in vivo use and therapeutic applications.

Details

Language :
English
ISSN :
2159-3345
Volume :
27
Issue :
3
Database :
MEDLINE
Journal :
Nucleic acid therapeutics
Publication Type :
Academic Journal
Accession number :
28355131
Full Text :
https://doi.org/10.1089/nat.2016.0647